Skip to main content
Top
Published in: Journal of Cardiovascular Magnetic Resonance 1/2017

Open Access 01-12-2017 | Research

Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods

Authors: Mateusz Śpiewak, Mariusz Kłopotowski, Monika Gawor, Agata Kubik, Ewa Kowalik, Barbara Miłosz-Wieczorek, Maciej Dąbrowski, Konrad Werys, Łukasz Mazurkiewicz, Katarzyna Kożuch, Magdalena Polańska-Skrzypczyk, Joanna Petryka-Mazurkiewicz, Anna Klisiewicz, Zofia T. Bilińska, Jacek Grzybowski, Adam Witkowski, Magdalena Marczak

Published in: Journal of Cardiovascular Magnetic Resonance | Issue 1/2017

Login to get access

Abstract

Background

Cardiovascular magnetic resonance (CMR) imaging in patients with hypertrophic cardiomyopathy (HCM) enables the assessment of not only left ventricular (LV) hypertrophy and scarring but also the severity of mitral regurgitation. CMR assessment of mitral regurgitation is primarily based on the difference between LV stroke volume (LVSV) and aortic forward flow (Ao) measured using the phase-contrast (PC) technique. However, LV outflow tract (LVOT) obstruction causing turbulent, non-laminar flow in the ascending aorta may impact the accuracy of aortic flow quantification, leading to false conclusions regarding mitral regurgitation severity. Thus, we decided to quantify mitral regurgitation in patients with HCM using Ao or, alternatively, main pulmonary artery forward flow (MPA) for mitral regurgitation volume (MRvol) calculations.

Methods

The analysis included 143 prospectively recruited subjects with HCM and 15 controls. MRvol was calculated as the difference between LVSV computed with either the inclusion (LVSVincl) or exclusion (LVSVexcl) of papillary muscles and trabeculations from the blood pool and either Ao (MRvolAoi or MRvolAoe) or MPA (MRvolMPAi or MRvolMPAe). The presence or absence of LVOT obstruction was determined based on Doppler echocardiography findings.

Results

MRvolAoi was higher than MRvolMPAi in HCM patients with LVOT obstruction [47.0 ml, interquartile range (IQR) = 31.5–60.0 vs. 35.5 ml, IQR = 26.0–51.0; p < 0.0001] but not in non-obstructive HCM patients (23.0 ml, IQR = 16.0–32.0 vs. 24.0 ml, IQR = 15.3–32.0; p = 0.26) or controls (18.0 ml, IQR = 14.3–21.8 vs. 20.0 ml, IQR = 14.3–22.0; p = 0.89). In contrast to controls and HCM patients without LVOT obstruction, in HCM patients with LVOT obstruction, aortic flow-based MRvol (MRvolAoi) was higher than pulmonary-based findings (MRvolMPAi) (bias = 9.5 ml; limits of agreement: −11.7–30.7 with a difference of 47 ml in the extreme case). The differences between aortic-based and pulmonary-based MRvol values calculated using LVSVexcl mirrored those derived using LVSVincl. However, MRvol values calculated using LVSVexcl were lower in all the groups analyzed (HCM with LVOT obstruction, HCM without LVOT obstruction, and controls) and with all methods of MRvol quantification used (p ≤ 0.0001 for all comparisons).

Conclusions

In HCM patients, LVOT obstruction significantly affects the estimation of aortic flow, leading to its underestimation and, consequently, to higher MRvol values than those obtained with MPA-based MRvol calculations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–9.CrossRefPubMed Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–9.CrossRefPubMed
2.
go back to reference Hong JH, Schaff HV, Nishimura RA, Abel MD, Dearani JA, Li Z, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol. 2016;68:1497–504.CrossRefPubMed Hong JH, Schaff HV, Nishimura RA, Abel MD, Dearani JA, Li Z, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol. 2016;68:1497–504.CrossRefPubMed
3.
go back to reference Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and Management of Hypertrophic Cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRefPubMed Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC guidelines on diagnosis and Management of Hypertrophic Cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRefPubMed
4.
go back to reference Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy a test in context. J Am Coll Cardiol. 2016;67:1846–58.CrossRefPubMed Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy a test in context. J Am Coll Cardiol. 2016;67:1846–58.CrossRefPubMed
5.
go back to reference Maron BJ, Maron MS. The remarkable 50 years of imaging in HCM and how it has changed diagnosis and management: from M-mode echocardiography to CMR. JACC Cardiovasc Imaging. 2016;9:858–72.CrossRefPubMed Maron BJ, Maron MS. The remarkable 50 years of imaging in HCM and how it has changed diagnosis and management: from M-mode echocardiography to CMR. JACC Cardiovasc Imaging. 2016;9:858–72.CrossRefPubMed
7.
go back to reference Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783–831.CrossRefPubMed Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783–831.CrossRefPubMed
8.
go back to reference Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’Andrea A, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16:280.CrossRefPubMed Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’Andrea A, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging. 2015;16:280.CrossRefPubMed
9.
go back to reference Choudhury L, Rigolin VH, Bonow RO. Integrated imaging in hypertrophic cardiomyopathy. Am J Cardiol. 2017;119:328–39.CrossRefPubMed Choudhury L, Rigolin VH, Bonow RO. Integrated imaging in hypertrophic cardiomyopathy. Am J Cardiol. 2017;119:328–39.CrossRefPubMed
10.
go back to reference Uretsky S, Supariwala A, Nidadovolu P, Khokhar SS, Comeau C, Shubayev O, et al. Quantification of left ventricular remodeling in response to isolated aortic or mitral regurgitation. J Cardiovasc Magn Reson. 2010;12:32.CrossRefPubMedPubMedCentral Uretsky S, Supariwala A, Nidadovolu P, Khokhar SS, Comeau C, Shubayev O, et al. Quantification of left ventricular remodeling in response to isolated aortic or mitral regurgitation. J Cardiovasc Magn Reson. 2010;12:32.CrossRefPubMedPubMedCentral
11.
go back to reference Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori L, et al. Prospective comparison of valve regurgitation quantitation by cardiac magnetic resonance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging. 2013;6:48–57.CrossRefPubMed Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori L, et al. Prospective comparison of valve regurgitation quantitation by cardiac magnetic resonance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging. 2013;6:48–57.CrossRefPubMed
12.
go back to reference Krieger EV, Lee J, Branch KR, Hamilton-Craig C. Quantitation of mitral regurgitation with cardiac magnetic resonance imaging: a systematic review. Heart. 2016;102:1864–70.CrossRefPubMed Krieger EV, Lee J, Branch KR, Hamilton-Craig C. Quantitation of mitral regurgitation with cardiac magnetic resonance imaging: a systematic review. Heart. 2016;102:1864–70.CrossRefPubMed
13.
go back to reference Chan KM, Wage R, Symmonds K, Rahman-Haley S, Mohiaddin RH, Firmin DN, et al. Towards comprehensive assessment of mitral regurgitation using cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:61.CrossRefPubMedPubMedCentral Chan KM, Wage R, Symmonds K, Rahman-Haley S, Mohiaddin RH, Firmin DN, et al. Towards comprehensive assessment of mitral regurgitation using cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:61.CrossRefPubMedPubMedCentral
14.
go back to reference Muzzarelli S, Monney P, O’Brien K, Faletra F, Moccetti T, Vogt P, et al. Quantification of aortic flow by phase-contrast magnetic resonance in patients with bicuspid aortic valve. Eur Heart J Cardiovasc Imaging. 2014;15:77–84.CrossRefPubMed Muzzarelli S, Monney P, O’Brien K, Faletra F, Moccetti T, Vogt P, et al. Quantification of aortic flow by phase-contrast magnetic resonance in patients with bicuspid aortic valve. Eur Heart J Cardiovasc Imaging. 2014;15:77–84.CrossRefPubMed
15.
go back to reference O’Brien KR, Cowan BR, Jain M, Stewart RA, Kerr AJ, Young AA. MRI phase contrast velocity and flow errors in turbulent stenotic jets. J Magn Reson Imaging. 2008;28:210–8.CrossRefPubMed O’Brien KR, Cowan BR, Jain M, Stewart RA, Kerr AJ, Young AA. MRI phase contrast velocity and flow errors in turbulent stenotic jets. J Magn Reson Imaging. 2008;28:210–8.CrossRefPubMed
16.
go back to reference Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–71.CrossRefPubMed Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30:303–71.CrossRefPubMed
17.
go back to reference Fratz S, Chung T, Greil GF, Samyn MM, Taylor AM, Valsangiacomo Buechel ER, et al. Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease. J Cardiovasc Magn Reson. 2013;15:51.CrossRefPubMedPubMedCentral Fratz S, Chung T, Greil GF, Samyn MM, Taylor AM, Valsangiacomo Buechel ER, et al. Guidelines and protocols for cardiovascular magnetic resonance in children and adults with congenital heart disease: SCMR expert consensus group on congenital heart disease. J Cardiovasc Magn Reson. 2013;15:51.CrossRefPubMedPubMedCentral
18.
go back to reference Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.CrossRefPubMedPubMedCentral Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.CrossRefPubMedPubMedCentral
19.
go back to reference Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the Management of Valvular Heart Disease (version 2012): the joint task force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;33:2451–96.CrossRefPubMed Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the Management of Valvular Heart Disease (version 2012): the joint task force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;33:2451–96.CrossRefPubMed
20.
go back to reference Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307–32.CrossRefPubMed Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tribouilloy C, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307–32.CrossRefPubMed
21.
go back to reference Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159–e95.CrossRefPubMed Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the Management of Patients with Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159–e95.CrossRefPubMed
22.
go back to reference Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57–185.CrossRefPubMed Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57–185.CrossRefPubMed
23.
go back to reference Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2011;24:473–98.CrossRefPubMed Nagueh SF, Bierig SM, Budoff MJ, Desai M, Dilsizian V, Eidem B, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2011;24:473–98.CrossRefPubMed
24.
go back to reference Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefPubMed Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefPubMed
26.
go back to reference Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255–68.CrossRefPubMed Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255–68.CrossRefPubMed
27.
go back to reference Allen BD, Choudhury L, Barker AJ, van Ooij P, Collins JD, Bonow RO, et al. Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiacmagnetic resonance. Eur Heart J Cardiovasc Imaging. 2015;16:29–36.CrossRefPubMed Allen BD, Choudhury L, Barker AJ, van Ooij P, Collins JD, Bonow RO, et al. Three-dimensional haemodynamics in patients with obstructive and non-obstructive hypertrophic cardiomyopathy assessed by cardiacmagnetic resonance. Eur Heart J Cardiovasc Imaging. 2015;16:29–36.CrossRefPubMed
28.
go back to reference Chu LC, Porter KK, Corona-Villalobos CP, Gülsün MA, Shea SM, Markl M, et al. Evaluation of left ventricular outflow tract obstruction with four-dimensional phase contrast magnetic resonance imaging in patients with hypertrophic cardiomyopathy—a pilot study. J Comput Assist Tomogr. 2016;40:937–40.CrossRefPubMed Chu LC, Porter KK, Corona-Villalobos CP, Gülsün MA, Shea SM, Markl M, et al. Evaluation of left ventricular outflow tract obstruction with four-dimensional phase contrast magnetic resonance imaging in patients with hypertrophic cardiomyopathy—a pilot study. J Comput Assist Tomogr. 2016;40:937–40.CrossRefPubMed
29.
go back to reference Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson. 2013;15:35.CrossRefPubMedPubMedCentral Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J Cardiovasc Magn Reson. 2013;15:35.CrossRefPubMedPubMedCentral
30.
go back to reference Han YC, Osborn EA, Maron MS, Manning WJ, Yeon SB. Impact of papillary and trabecular muscles on quantitative analyses of cardiac function in hypertrophic cardiomyopathy. J Magn Reson Imaging. 2009;30:1197–202.CrossRefPubMed Han YC, Osborn EA, Maron MS, Manning WJ, Yeon SB. Impact of papillary and trabecular muscles on quantitative analyses of cardiac function in hypertrophic cardiomyopathy. J Magn Reson Imaging. 2009;30:1197–202.CrossRefPubMed
31.
go back to reference Gommans DHF, Bakker J, Cramer GE, Verheugt FWA, Brouwer MA, Kofflard MJM. Impact of the papillary muscles on cardiac magnetic resonance image analysis of important left ventricular parameters in hypertrophic cardiomyopathy. Neth Heart J. 2016;24:326–31.CrossRefPubMedPubMedCentral Gommans DHF, Bakker J, Cramer GE, Verheugt FWA, Brouwer MA, Kofflard MJM. Impact of the papillary muscles on cardiac magnetic resonance image analysis of important left ventricular parameters in hypertrophic cardiomyopathy. Neth Heart J. 2016;24:326–31.CrossRefPubMedPubMedCentral
32.
go back to reference Chuang ML, Gona P, Hautvast GL, Salton CJ, Blease SJ, Yeon SB, et al. Correlation of trabeculae and papillary muscles with clinical and cardiac characteristics and impact on CMR measures of LV anatomy and function. JACC Cardiovasc Imaging. 2012;5:1115–23.CrossRefPubMedPubMedCentral Chuang ML, Gona P, Hautvast GL, Salton CJ, Blease SJ, Yeon SB, et al. Correlation of trabeculae and papillary muscles with clinical and cardiac characteristics and impact on CMR measures of LV anatomy and function. JACC Cardiovasc Imaging. 2012;5:1115–23.CrossRefPubMedPubMedCentral
33.
go back to reference Kozor R, Callaghan F, Tchan M, Hamilton-Craig C, Figtree GA, Grieve SM. A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. J Cardiovasc Magn Reson. 2015;17:22.CrossRefPubMedPubMedCentral Kozor R, Callaghan F, Tchan M, Hamilton-Craig C, Figtree GA, Grieve SM. A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. J Cardiovasc Magn Reson. 2015;17:22.CrossRefPubMedPubMedCentral
34.
go back to reference Park EA, Lee W, Kim HK, Chung JW. Effect of papillary muscles and trabeculae on left ventricular measurement using cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Korean J Radiol. 2015;16:4–12.CrossRefPubMedPubMedCentral Park EA, Lee W, Kim HK, Chung JW. Effect of papillary muscles and trabeculae on left ventricular measurement using cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Korean J Radiol. 2015;16:4–12.CrossRefPubMedPubMedCentral
35.
go back to reference Sievers B, Kirchberg S, Bakan A, Franken U, Trappe HJ. Impact of papillary muscles in ventricular volume and ejection fraction assessment by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2004;6:9–16.CrossRefPubMed Sievers B, Kirchberg S, Bakan A, Franken U, Trappe HJ. Impact of papillary muscles in ventricular volume and ejection fraction assessment by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2004;6:9–16.CrossRefPubMed
36.
go back to reference Papavassiliu T, Kuhl HP, Schroder M, Suselbeck T, Bondarenko O, Bohm CK, et al. Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging. Radiology. 2005;236:57–64.CrossRefPubMed Papavassiliu T, Kuhl HP, Schroder M, Suselbeck T, Bondarenko O, Bohm CK, et al. Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging. Radiology. 2005;236:57–64.CrossRefPubMed
37.
go back to reference Vogel-Claussen J, Finn JP, Gomes AS, Hundley GW, Jerosch-Herold M, Pearson G, et al. Left ventricular papillary muscle mass: relationship to left ventricular mass and volumes by magnetic resonance imaging. J Comput Assist Tomogr. 2006;30:426–32.CrossRefPubMed Vogel-Claussen J, Finn JP, Gomes AS, Hundley GW, Jerosch-Herold M, Pearson G, et al. Left ventricular papillary muscle mass: relationship to left ventricular mass and volumes by magnetic resonance imaging. J Comput Assist Tomogr. 2006;30:426–32.CrossRefPubMed
38.
go back to reference Janik M, Cham MD, Ross MI, Wang Y, Codella N, Min JK, et al. Effects of papillary muscles and trabeculae on left ventricular quantification: increased impact of methodological variability in patients with left ventricular hypertrophy. J Hypertens. 2008;26:1677–85.CrossRefPubMed Janik M, Cham MD, Ross MI, Wang Y, Codella N, Min JK, et al. Effects of papillary muscles and trabeculae on left ventricular quantification: increased impact of methodological variability in patients with left ventricular hypertrophy. J Hypertens. 2008;26:1677–85.CrossRefPubMed
39.
go back to reference Weinsaft JW, Cham MD, Janik M, Min JK, Henschke CI, Yankelevitz DF, et al. Left ventricular papillary muscles and trabeculae are significant determinants of cardiac MRI volumetric measurements: effects on clinical standards in patients with advanced systolic dysfunction. Int J Cardiol. 2008;126:359–65.CrossRefPubMed Weinsaft JW, Cham MD, Janik M, Min JK, Henschke CI, Yankelevitz DF, et al. Left ventricular papillary muscles and trabeculae are significant determinants of cardiac MRI volumetric measurements: effects on clinical standards in patients with advanced systolic dysfunction. Int J Cardiol. 2008;126:359–65.CrossRefPubMed
40.
go back to reference Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:668–73.CrossRefPubMed Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:668–73.CrossRefPubMed
41.
go back to reference Meierhofer C, Lyko C, Schneider EP, Stern H, Martinoff S, Hess J, et al. Baseline correction does not improve flow quantification in phase-contrast velocity measurement for routine clinical practice. Clin Imaging. 2015;39:427–31.CrossRefPubMed Meierhofer C, Lyko C, Schneider EP, Stern H, Martinoff S, Hess J, et al. Baseline correction does not improve flow quantification in phase-contrast velocity measurement for routine clinical practice. Clin Imaging. 2015;39:427–31.CrossRefPubMed
42.
go back to reference Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212–60.CrossRefPubMed Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212–60.CrossRefPubMed
43.
go back to reference Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation. 1998;97:461–6.CrossRefPubMed Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation. 1998;97:461–6.CrossRefPubMed
44.
go back to reference Geske JB, Sorajja P, Ommen SR, Nishimura RA. Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy. Clin Cardiol. 2009;32:397–402.CrossRefPubMed Geske JB, Sorajja P, Ommen SR, Nishimura RA. Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy. Clin Cardiol. 2009;32:397–402.CrossRefPubMed
45.
go back to reference Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4:704–9.CrossRefPubMed Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4:704–9.CrossRefPubMed
46.
go back to reference Kramer CM, Appelbaum E, Desai MY, Desvigne-Nickens P, DiMarco JP, Friedrich MG, et al. Hypertrophic Cardiomyopathy registry: the rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015;170:223–30.CrossRefPubMedPubMedCentral Kramer CM, Appelbaum E, Desai MY, Desvigne-Nickens P, DiMarco JP, Friedrich MG, et al. Hypertrophic Cardiomyopathy registry: the rationale and design of an international, observational study of hypertrophic cardiomyopathy. Am Heart J. 2015;170:223–30.CrossRefPubMedPubMedCentral
47.
go back to reference Kwong RY, Petersen SE, Schulz-Menger J, Arai AE, Bingham SE, Chen Y, et al. The Global Cardiovascular Magnetic Resonance Registry (GCMR) of the Society for Cardiovascular Magnetic Resonance (SCMR): its goals, rationale, data infrastructure, and current developments. J Cardiovasc Magn Reson. 2017;19:23.CrossRefPubMedPubMedCentral Kwong RY, Petersen SE, Schulz-Menger J, Arai AE, Bingham SE, Chen Y, et al. The Global Cardiovascular Magnetic Resonance Registry (GCMR) of the Society for Cardiovascular Magnetic Resonance (SCMR): its goals, rationale, data infrastructure, and current developments. J Cardiovasc Magn Reson. 2017;19:23.CrossRefPubMedPubMedCentral
Metadata
Title
Quantification of mitral regurgitation in patients with hypertrophic cardiomyopathy using aortic and pulmonary flow data: impacts of left ventricular outflow tract obstruction and different left ventricular segmentation methods
Authors
Mateusz Śpiewak
Mariusz Kłopotowski
Monika Gawor
Agata Kubik
Ewa Kowalik
Barbara Miłosz-Wieczorek
Maciej Dąbrowski
Konrad Werys
Łukasz Mazurkiewicz
Katarzyna Kożuch
Magdalena Polańska-Skrzypczyk
Joanna Petryka-Mazurkiewicz
Anna Klisiewicz
Zofia T. Bilińska
Jacek Grzybowski
Adam Witkowski
Magdalena Marczak
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Cardiovascular Magnetic Resonance / Issue 1/2017
Electronic ISSN: 1532-429X
DOI
https://doi.org/10.1186/s12968-017-0417-8

Other articles of this Issue 1/2017

Journal of Cardiovascular Magnetic Resonance 1/2017 Go to the issue